Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy

Tumor cells are particularly dependent on NAD(+) due to higher rates of metabolism, DNA synthesis and repair. Nicotinamide phosphoribosyltransferase inhibitors (NAMPTis) inhibit NAD(+) biosynthesis and represent promising new anti-cancer agents. However, clinical efficacy has been limited by toxicit...

Descripción completa

Detalles Bibliográficos
Autores principales: Cole, Jonathan, Guiot, Marie-Christine, Gravel, Michel, Bernier, Cynthia, Shore, Gordon C., Roulston, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652819/
https://www.ncbi.nlm.nih.gov/pubmed/29100430
http://dx.doi.org/10.18632/oncotarget.20840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652819/
https://www.ncbi.nlm.nih.gov/pubmed/29100430
http://dx.doi.org/10.18632/oncotarget.20840

Ejemplares similares